MITSI LONG: Open Payments
NPI 1740801752 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$784 in 38 payments from 8 companies in 2025. Trend: 2023 $1,695 · 2024 $1,199 · 2025 $784
Food & beverage: $694Education: $90
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $399 |
| Teva Pharmaceuticals USA, Inc. | 10 | $205 |
| Janssen Pharmaceuticals, Inc | 5 | $89 |
| Alkermes, Inc. | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ABBVIE INC. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: INGREZZA, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA, COBENFY, UZEDY, VRAYLAR, ABILIFY ASIMTUFII.
Industry payments across LA — which companies pay providers there.
